[et_pb_section fb_built=“1″ fullwidth=“on“ _builder_version=“4.16″ da_disable_devices=“off|off|off“ global_colors_info=“{}“ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_fullwidth_slider use_text_overlay=“on“ text_overlay_color=“rgba(6,66,58,0.25)“ _builder_version=“4.16″ custom_padding=“83px||65px|||“ auto=“on“ auto_ignore_hover=“on“ global_colors_info=“{}“][et_pb_slide heading=“Ver\u00f6ffentlichungen“ use_bg_overlay=“off“ use_text_overlay=“on“ arrows_custom_color=“#2d788c“ dot_nav_custom_color=“#2d788c“ text_border_radius=“10px“ _builder_version=“4.16″ header_font=“|700|||||||“ header_text_align=“center“ body_text_align=“center“ background_enable_color=“off“ use_background_color_gradient=“on“ background_color_gradient_direction=“90deg“ background_color_gradient_stops=“rgba(0,0,0,0) 0%|rgba(0,0,0,0) 100%“ background_color_gradient_overlays_image=“on“ background_color_gradient_start=“rgba(0,0,0,0)“ background_color_gradient_end=“rgba(0,0,0,0)“ background_image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/3d-objects-of-hepatitis-b-viruses-in-abstract-plasma.jpg“ background_enable_image=“on“ text_orientation=“center“ header_text_shadow_style=“preset1″ header_text_shadow_color=“#706f6f“ body_text_shadow_style=“preset1″ body_text_shadow_color=“#706f6f“ text_shadow_style=“preset1″ text_shadow_color=“#706f6f“ global_colors_info=“{}“ sticky_transition=“on“][\/et_pb_slide][\/et_pb_fullwidth_slider][\/et_pb_section][et_pb_section fb_built=“1″ _builder_version=“4.16″ da_disable_devices=“off|off|off“ global_colors_info=“{}“ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_row module_id=“press“ _builder_version=“4.16″ custom_padding=“||0px|||“ global_colors_info=“{}“][et_pb_column type=“4_4″ _builder_version=“4.16″ global_colors_info=“{}“][et_pb_text _builder_version=“4.25.0″ custom_padding=“||0px|||“ global_colors_info=“{}“]<\/p>\n
Find here relevant scientific publications and technical articles – including from TherVacB project partners. Scroll down to read more about chronic hepatitis B, the virus, screening and testing for viral hepatitis C, B and D, therapeutic vaccination, and cure research as welll as ethical and practical considerations of patient recruitment into clinical trials<\/span>.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“][et_pb_blurb title=“Towards a cure for hepatitis B – EC CORDIS platform features the TherVacB project“ alt=“Social Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study“ icon_placement=“left“ admin_label=“20230522″ module_class=“blurbpublications“ _builder_version=“4.25.0″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ hover_enabled=“0″ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“ sticky_enabled=“0″]<\/p>\n 8 August 2025 | EU CORDIS News \u2013 European Commission<\/span><\/p>\n The European Commission\u2019s Community Research and Development Information Service, the CORDIS platform, features the TherVacB project for advancing a therapeutic vaccine against chronic hepatitis B (HBV). The article highlights the start of the multinational trial in summer 2025 and recognises TherVacB\u2019s contribution to developing curative, immune-based therapies for HBV. Read the article directly on the CORDIS platform in English, German, Spanish, Italian, and other languages. <\/p>\n https:\/\/cordis.europa.eu\/article\/id\/461120-towards-a-cure-for-hepatitis-b [\/et_pb_blurb][et_pb_blurb title=“Perceptions of stigma among patients with hepatitis B in Germany: Cross-sectional survey“ alt=“Social Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study“ icon_placement=“left“ admin_label=“20230522″ module_class=“blurbpublications“ _builder_version=“4.25.0″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 13 June 2025 | JMIR Human Factors, Volume 9 (2025)<\/span><\/p>\n The key question discussed in this scientific publication is: How do people in Germany experience stigma related to hepatitis B? Most interdisciplinary research on hepatitis B stigma comes from outside Europe. To address this gap, TherVacB team at the Institute of History and Ethics in Medicine at TUM-MRI (Munich, Germany)<\/a> conducted a study with 195 patients across Germany, supported by TherVacB clinical centres in Munich, Hannover, and Leipzig<\/a>. The findings show that individuals who speak a language other than German, place a high value on privacy, or keep their diagnosis secret are more likely to feel stigmatized. In contrast, age, gender, and education had no influence on perceived stigma. While stigma levels were generally lower than in studies from Asia, cultural and social factors still play a key role. These results from TherVacB underline the need to raise awareness among healthcare professionals and support targeted community outreach. <\/p>\n https:\/\/formative.jmir.org\/2025\/1\/e66379\/<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=“Scientific and medical evidence informing expansion of hepatitis B treatment guidelines“ alt=“Social Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study“ icon_placement=“left“ admin_label=“20230522″ module_class=“blurbpublications“ _builder_version=“4.25.0″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 23 July 2025 | The Lancet Gastroenterology & Hepatology<\/span><\/p>\n This scientific article explores whether current treatment guidelines for hepatitis B are too narrow\u2014and whether more people could benefit from antiviral therapy. Today\u2019s treatments can suppress the virus and protect the liver, but they do not offer a cure. Global guidelines typically recommend treatment only for people with high viral load and signs of liver damage\u2014criteria that often require testing not widely available in low-resource settings. As a result, fewer than 3% of people living with hepatitis B currently receive treatment. This article discusses the risks and benefits of expanding treatment eligibility, highlighting the potential for earlier and broader intervention to reduce long-term liver damage and cancer risk. TherVacB researchers Markus Cornberg and Patrick Kennedy, together with Thomas Tu (ICE-HBV) and others, contributed to this important publication, which supports global hepatitis B elimination goals by promoting more inclusive treatment strategies. <\/p>\n https:\/\/www.thelancet.com\/journals\/langas\/article\/PIIS2468-1253(25)00053-6\/abstract<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=“Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines“ alt=“Social Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study“ icon_placement=“left“ admin_label=“20230522″ module_class=“blurbpublications“ _builder_version=“4.25.0″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 23 July 2025 | The Lancet Gastroenterology & Hepatology<\/span><\/p>\n This scientific article discusses the need to broaden access to hepatitis B treatment as part of a global public health strategy. Expanding treatment could improve lives and support progress toward hepatitis B elimination. Chronic infection affects millions worldwide and has serious physical, emotional, and social impacts. While antiviral therapy can prevent liver damage and improve quality of life, access remains limited\u2014especially in low-resource settings. The authors argue that treatment decisions should consider public health and patient-centred perspectives, not just clinical criteria. They highlight the benefits of earlier access, including reduced disease burden and better outcomes, and outline implementation challenges and data gaps. The publication was led by an international team of researchers from the Hepatitis B Foundation, ICE-HBV, the World Hepatitis Alliance, and academic centres in the US, UK, Australia, Egypt, and Europe. Together, they call for a more inclusive approach to treatment that supports global hepatitis B elimination goals. <\/p>\n https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S2468125325000524?dgcid=author<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=“EASL Clinical Practice Guidelines on the management of hepatitis B virus infect“ alt=“Social Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study“ icon_placement=“left“ admin_label=“20230522″ module_class=“blurbpublications“ _builder_version=“4.25.0″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n August 2025, first published online 9 May 2025 | Journal of Hepatology, Volume 83<\/span><\/p>\n Updated clinical guideline supports better care for hepatitis B worldwide: Hepatitis B remains a major global health challenge, with over 250 million people affected and many at risk of serious liver disease. The newly updated clinical practice guideline from the European Association for the Study of the Liver (EASL) provides practical, evidence-based recommendations to improve diagnosis, treatment, and long-term care. It is designed for all healthcare professionals involved in HBV care, from general practitioners to specialists, and includes specific guidance for both high- and low-resource settings. The guideline highlights the importance of early detection, personalised care, simplified treatment approaches, and new definitions of functional cure. TherVacB team researchers Markus Cornberg (Chair of the EASL Clinical Practice Guideline Panel), Patrick Kennedy, and Sabela Lens contributed \u2013 with other scientists – in developing this important tool, which supports the global goal of hepatitis B elimination. <\/p>\n https:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(25)00174-6\/fulltext?s=35<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=“Social Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study “ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/social-media-recruitment-as-a-potential-trigger-for-vulnerability-multistakeholder-interview-study.png“ alt=“Social Media Recruitment as a Potential Trigger for Vulnerability: Multistakeholder Interview Study“ icon_placement=“left“ admin_label=“20230522″ module_class=“blurbpublications“ _builder_version=“4.25.0″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 30 December 2024 | JMIR Human Factors, Volume 11<\/span><\/p>\n Clinical studies increasingly use social media to recruit participants, yet little research has examined the ethical challenges\u2014especially when targeting individuals in vulnerable situations. This study explores expert and patient perspectives on how social media recruitment can both reduce and amplify vulnerabilities. As part of the international TherVacB EU research project testing a hepatitis B vaccine, the authors conducted 30 interviews with external experts from various fields and 6 patients with hepatitis B. Insights from the study offer practical guidance for minimizing risks while maintaining the benefits of social media recruitment. The study highlights the need for researchers to anticipate ethical challenges and proactively apply strategies that promote both inclusivity and participant protection. <\/p>\n https:\/\/humanfactors.jmir.org\/2024\/1\/e52448<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=“The urgent need to end hepatitis B stigma and discrimination“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/The-urgent-need-to-end-hepatitis-B-stigma-and-discrimination.png“ alt=“The urgent need to end hepatitis B stigma and discrimination“ icon_placement=“left“ admin_label=“20230522″ module_class=“blurbpublications“ _builder_version=“4.25.0″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 17 December 2024 \/ 10 January 2025 | The Lancet Gastroenterology & Hepatology, Volume 10<\/span><\/p>\n In this article, authors call for prioritization to end hepatitis B-related discrimination, taking into account the WHO global hepatitis report 2024.<\/p>\n https:\/\/www.thelancet.com\/journals\/langas\/article\/PIIS2468-1253(24)00389-3\/abstract<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=“A cancer-causing virus hiding in millions of Americans. Why does hepatitis B, which can lead to liver cancer, often go undetected, even though tests exist? “ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/a-cancer-causing-virus-hiding-in-millions-of-americans.jpg“ alt=“A Cancer-Causing Virus Hiding in Millions of Americans“ icon_placement=“left“ admin_label=“20230522″ module_class=“blurbpublications“ _builder_version=“4.25.0″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 18 December 2024 | The New Yorker<\/span><\/p>\n The major U.S. popular media magazine The New Yorker prioritizes hepatitis B and its health disparities in the USA. Hepatitis B Foundation President Dr. Chari Cohen is quoted in a powerful new story about hepatitis B. <\/p>\n https:\/\/www.newyorker.com\/science\/annals-of-medicine\/a-cancer-causing-virus-hiding-in-millions-of-americans<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=“Acceptance of Social Media Recruitment for Clinical Studies Among Patients With Hepatitis B: Mixed Methods Study“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/acceptance-of-social-media-recruitment-for-clinical-studies-among-patients-with-hepatitis-b.png“ alt=“Acceptance of Social Media Recruitment for Clinical Studies Among Patients With Hepatitis B“ icon_placement=“left“ admin_label=“20230522″ module_class=“blurbpublications“ _builder_version=“4.25.0″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]26 August 2024 | Journal of Medical Internet Research<\/em><\/span><\/p>\n This study focuses on patients with hepatitis B in Germany and examines their attitudes toward using social media<\/strong> platforms like Facebook<\/strong> and Twitter<\/strong> for recruiting participants into clinical trials<\/strong>. Hepatitis B is a chronic infectious disease<\/strong>, and patients with this condition are often seen as vulnerable, facing potential stigma<\/strong> and discrimination<\/strong>. Researchers at TherVacB\u2019s TUM-MED and at TUM, University of Bern and University of Basel surveyed 195 patients from three clinical centres in Germany and found that factors like digital literacy<\/strong>, trust in nonmedical sources, privacy<\/strong> concerns, and willingness to share their diagnosis impact their acceptance of social media recruitment. The study emphasizes how understanding these factors, including health technology acceptance<\/strong>, can help researchers design recruitment strategies while balancing ethics<\/strong> and data protection<\/strong> considerations, especially in this vulnerable group. These insights could improve enrolment<\/strong> for clinical studies in the future. <\/p>\n https:\/\/www.jmir.org\/2024\/1\/e54034<\/a>[\/et_pb_blurb][et_pb_blurb title=“Practical Benefits, Challenges, and Recommendations on Social Media Recruitment: Multi-Stakeholder Interview Study“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/practical-benefits-challenges-and-recommendations-on-social-media-recruitment-multi-stakeholder-interview-study.png“ alt=“Practical Benefits, Challenges, and Recommendations on Social Media Recruitment: Multi-Stakeholder Interview Study“ icon_placement=“left“ admin_label=“20230522″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]22 May 2023 | Journal of Medical Internet Research<\/em><\/span><\/p>\n The increasing use of social media opens new opportunities for recruiting patients for research studies. Based on semi-structured interviews with both people using social media and living with hepatitis B as well as experts in a range of disciplines, authors are exploring the practical benefits of recruiting study participants with social media and are sharing an expert summary on how to conduct social media-based recruitment. Generally, a multiplatform approach with mixed-methods recruitment is the most beneficial recruitment strategy for many research studies. The different recruitment methods complement each other and may contribute to improving the reach of the study, the recruitment accrual, and the representativeness of the sample. Importantly, an assessment of the context- and project-specific appropriateness and usefulness of social media recruitment should be carried out before designing the recruitment strategy. <\/p>\n https:\/\/www.jmir.org\/2023\/1\/e44587\/ <\/a>[\/et_pb_blurb][et_pb_blurb title=“Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/efficient-stabilizatio-nof-therapeutic-hepatitis-b-vaccine-components.png“ alt=“Efficient stabilization of therapeutic hepatitis B vaccine components“ icon_placement=“left“ admin_label=“20221012″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n February 2023 | Journal of Hepatology<\/em><\/span><\/p>\n Induction of potent, HBV-specific immune responses is crucial to control and finally cure HBV. The therapeutic hepatitis B vaccine TherVacB<\/em> combines protein priming with a Modified Vaccinia virus Ankara (MVA)-vector boost to break immune tolerance in chronic HBV infection. Particulate protein and vector vaccine components, however, require a constant cooling chain for storage and transport, posing logistic and financial challenges to vaccine applications. Authors of this article aimed to identify an optimal formulation to maintain stability and immunogenicity of the protein and vector components of the vaccine using a systematic approach. This will facilitate global vaccine application without the need for cooling chains and is important for the development of prophylactic as well as therapeutic vaccines supporting vaccination campaigns worldwide.<\/p>\n https:\/\/www.jhep-reports.eu\/article\/S2589-5559%2822%2900175-6\/fulltext<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=“Social media advertising for clinical studies: Ethical and data protection implications of online targeting“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/social-media-advertising-for-clinical-studies.png“ alt=“Social media advertising for clinical studies“ icon_placement=“left“ admin_label=“20221012″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 21 February 2023 | Big Data & Society<\/em><\/span><\/p>\n Social media advertising is gaining a foothold in the recruitment of clinical study participants, promising more yield per money spent because the technology can better reach highly specialised groups. In this article, authors point out severe societal risks posed by advertising for clinical studies on social media and call for updates of research ethics guidelines and better regulation of Big Data and inferential analytics. In conclusion, social media advertising \u2013 especially with vulnerable patient populations \u2013 is deemed unsuitable as a recruitment tool for clinical studies as long as the processing of (even anonymised) social media usage data and the training of predictive models by data analytics and artificial intelligence companies is not sufficiently regulated.<\/p>\n https:\/\/journals.sagepub.com\/doi\/10.1177\/20539517231156127<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=“Bewertung der Auswirkung der CD70-Koexpression auf die CD8-T-Zell-Antwort bei der Protein-Prime-MVA-Boost-Impfung in M\u00e4usen“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/evaluation-of-the-effect-of-cd70-co-expression-on-cd8-t-cell-response.png“ alt=“Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response “ icon_placement=“left“ admin_label=“20221012″ module_class=“blurbpublications“ _builder_version=“4.21.0″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]21 January 2023 | Vaccines \u2013 Specia<\/em>l Issue <\/em>Hepatitis Virus Vaccine Immune Therapy<\/a><\/em><\/span><\/p>\n This article investigates the potential of CD70 co-expression during viral vector boost vaccination to improve an antigen-specific T cell response. In sum, the article presents a safe system to selectively enhance the vector-vaccine-induced CD8 T cell response to the target antigen through CD70 co-expression during boost immunization. In this respect, this study may contribute to the development and improvement of therapeutic vaccines revealing novel generic design principles and thus foster advances of current strategies to fight malignancies and persistent viral infections.<\/p>\n https:\/\/www.mdpi.com\/2076-393X\/11\/2\/245<\/a>[\/et_pb_blurb][et_pb_blurb title=“Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/activation-of-cd4-t-cells.png“ alt=“Activation of CD4 T cells “ icon_placement=“left“ admin_label=“20221012″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 9. Januar 2023 | Journal of Hepatology<\/span> Lesen Sie hier mehr \u00fcber die Arbeit des Teams um Prof. Dr. Ulrike Protzer und Dr. Anna Kosinska: https:\/\/idw-online.de\/en\/news807417<\/a> [\/et_pb_blurb][et_pb_blurb title=“Bewertung der Auswirkung der CD70-Koexpression auf die CD8-T-Zell-Antwort bei der Protein-Prime-MVA-Boost-Impfung in M\u00e4usen “ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/evaluation-of-the-effect-of-cd70-co-expression-on-cd8-t-cell.png“ alt=“Bewertung der Auswirkungen der Koexpression von CD70 auf CD8-T-Zellen“ icon_placement=“left“ admin_label=“20221012″ module_class=“blurbpublications“ _builder_version=“4.21.0″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 21. Januar 2023 | Vaccines – Special Issue Hepatitis Virus Vaccine Immune Therapy<\/span> [\/et_pb_blurb][et_pb_blurb title=“Ein thermostabiler therapeutischer Impfstoff ist in der Lage, die Immuntoleranz in einem Mausmodell f\u00fcr chronische Hepatitis B zu brechen“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/break-immune-tolerance-in-a-mouse-model-of-chronic-hepatitis-b.jpg“ alt=“Unterbrechung der Immuntoleranz in einem Mausmodell f\u00fcr chronische Hepatitis B“ icon_placement=“left“ admin_label=“20221012″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 12. Oktober 2022 | Journal of Hepatology (JHEP) Reports<\/span> Lesen Sie mehr \u00fcber die Arbeit des Teams im Labor von Prof. Protzer hier: https:<\/a>\/\/www.dzif.de\/en\/chronic-hepatitis-b-development-thermostable-therapeutic-vaccine. https:\/\/www.jhep-reports.eu\/article\/S2589-5559(22)00175-6\/fulltext<\/a><\/p>\n [\/et_pb_blurb][et_pb_blurb title=“Ein Fahrplan f\u00fcr Serum-Biomarker f\u00fcr das Hepatitis-B-Virus: aktueller Stand und Zukunftsaussichten“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/a-roadmap-for-serum-biomarkers-for-hepatitis-b-virus-current-status-and-future-outlook.png“ alt=“Ein Fahrplan f\u00fcr Serum-Biomarker f\u00fcr das Hepatitis-B-Virus: aktueller Stand und Zukunftsaussichten“ icon_placement=“left“ admin_label=“20220720″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]20 July 2022 | Nature Reviews Gastroenterology & Hepatology<\/span> 30. M\u00e4rz 2022 | Nature<\/span> [\/et_pb_blurb][et_pb_blurb title=“Immunogenit\u00e4t und antivirale Reaktion auf eine therapeutische Hepatitis-B-Impfung in einem Mausmodell mit HBeAg-negativer, persistierender HBV-Infektion“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/immunogenicity-and-antiviral-response-of-therapeutic-hepatitis-b-vaccination-in-a-mouse-model-of-hbeag-negative.png“ alt=“Einem Heilmittel f\u00fcr Hepatitis B auf der Spur“ icon_placement=“left“ admin_label=“20210731″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 31 July 2021 | Vaccines<\/span> [\/et_pb_blurb][et_pb_blurb title=“Hepatitis-B-, -C- und -D-Viruspr\u00e4valenz bei Kindern und Erwachsenen in der Region Mbeya, Tansania: Ergebnisse einer Kohortenstudie 2002 – 2009″ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/hepatitis-b-c-and-d-virus-prevalence-in-children-and-adults-in-mbeya-region-tanzania.png“ alt=“Hepatitis-B-, -C- und -D-Viruspr\u00e4valenz bei Kindern und Erwachsenen in der Region Mbeya, Tansania“ icon_placement=“left“ admin_label=“20210706″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ saved_tabs=“all“ global_colors_info=“{}“]<\/p>\n 6 July 2021 | The Pan African Medical Journal<\/span> [\/et_pb_blurb][et_pb_blurb title=“Screening auf Hepatitis B und C geh\u00f6rt jetzt zur Gesundheitsvorsorge“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/screening-auf-hepatitis-b-und-c-gehort-jetzt-zur-gesundheitsvorsorge.png“ alt=“Einem Heilmittel f\u00fcr Hepatitis B auf der Spur“ icon_placement=“left“ admin_label=“20210717″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 17 June 2021 | Der Hausarzt.DIGITAL<\/span> [\/et_pb_blurb][et_pb_blurb title=“Ausschaltung von PD-L1 in der Leber mit siRNAs erh\u00f6ht die Wirksamkeit der therapeutischen Impfung gegen chronische Hepatitis B“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/pd-l1-silencing-in-liver-using-sirnas-enhances-efficacy-of-therapeutic-vaccination-for-chronic-hepatitis-b.png“ alt=“Einem Heilmittel f\u00fcr Hepatitis B auf der Spur“ icon_placement=“left“ admin_label=“20210318″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n 18 March 2021 | Biomolecules <\/span> [\/et_pb_blurb][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" relevant Publications Find here relevant scientific publications and technical articles – including from TherVacB project partners. Scroll down to read more about chronic hepatitis B, the virus, screening and testing for viral hepatitis C, B and D, therapeutic vaccination, and cure research as welll as ethical and practical considerations of patient recruitment into clinical trials.8 […]<\/p>\n","protected":false},"author":5,"featured_media":2836,"parent":1993,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-8508","page","type-page","status-publish","has-post-thumbnail","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/pages\/8508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/comments?post=8508"}],"version-history":[{"count":16,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/pages\/8508\/revisions"}],"predecessor-version":[{"id":13771,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/pages\/8508\/revisions\/13771"}],"up":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/pages\/1993"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/media\/2836"}],"wp:attachment":[{"href":"https:\/\/www.thervacb.eu\/de\/wp-json\/wp\/v2\/media?parent=8508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n <\/a><\/p>\n
Die Autoren beschreiben das k\u00fcrzlich entwickelte heterologe therapeutische Impfschema(TherVacB)<\/em>, das aus einem partikul\u00e4ren Protein-Prime gefolgt von einem modifizierten Vacciniavirus Ankara (MVA)-Vektor-Boost zur Behandlung von HBV besteht.<\/em> Die Schl\u00fcsselfaktoren, die zur \u00dcberwindung der HBV-spezifischen Immuntoleranz erforderlich sind, bleiben jedoch unklar. In this article, new combination adjuvants and unravel factors are studied that are essential for the antiviral efficacy of the TherVacB<\/em> vaccination scheme.<\/p>\n
https:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(22)03465-1\/fulltext#secsectitle0045<\/a>
<\/em><\/p>\n
In diesem Artikel untersucht das Forscherteam das Potenzial der CD70-Koexpression w\u00e4hrend der viralen Vektor-Boost-Impfung zur Verbesserung einer antigenspezifischen T-Zell-Antwort. Insgesamt deutet diese Studie darauf hin, dass die orchestrierte Koexpression von CD70 und einem Impfstoff-Antigen ein interessantes und sicheres Mittel sein kann, um antigenspezifische CD8-T-Zell-Antworten mit vektorbasierten Impfstoffen zu verst\u00e4rken, obwohl dies in unserer Studie nicht ausreichte, um die Immuntoleranz zu brechen.
https:\/\/www.mdpi.com\/2076-393X\/11\/2\/245<\/a><\/p>\n
Die therapeutische Impfung ist eine vielversprechende Behandlungsm\u00f6glichkeit f\u00fcr chronische Hepatitis B, die eine Heilung der chronischen Hepatitis B erm\u00f6glichen k\u00f6nnte. Ihre Anwendung erfordert jedoch funktionierende K\u00fchlketten w\u00e4hrend des Transports und der Lagerung, die in vielen L\u00e4ndern mit hoher Nachfrage kaum gew\u00e4hrleistet werden k\u00f6nnen. In dieser Studie haben die Autoren, darunter Julia Sacherl, Anna D. Kosinska und Ulrike Protzer, thermostabile Impfstoffkomponenten entwickelt, die gut vertr\u00e4glich sind und es erm\u00f6glichen, in pr\u00e4klinischen Mausmodellen Immunantworten zu induzieren und das Virus auch nach langfristiger Exposition gegen\u00fcber hohen Umgebungstemperaturen zu kontrollieren. Dies wird die Kosten senken und die Anwendung eines therapeutischen Impfstoffs erleichtern und somit den vielen Hepatitis-B-Patienten weltweit zugute kommen.<\/p>\n
<\/em><\/p>\n
\nGlobally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes. Obwohl es einen pr\u00e4ventiven Impfstoff und antivirale Therapien gibt, die die HBV-Replikation unterdr\u00fccken, gibt es keine Heilung. Es werden intensive Anstrengungen unternommen, um kurative HBV-Therapien zu entwickeln. Derzeit gibt es nur wenige Biomarker f\u00fcr die \u00dcberwachung oder Vorhersage des Fortschreitens der HBV-Erkrankung und des Ansprechens auf die Behandlung. In dem Ma\u00dfe, in dem neue Therapien zur Verf\u00fcgung stehen, werden dringend neue Biomarker zur \u00dcberwachung der Reaktion von Virus und Wirt ben\u00f6tigt. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a workshop on HBV biomarkers. Verschiedene Akteure aus der Wissenschaft, der klinischen Praxis und der pharmazeutischen Industrie mit sich erg\u00e4nzenden Fachkenntnissen hielten Vortr\u00e4ge und nahmen an Podiumsdiskussionen teil, darunter Ulrike Protzer, Mala Maini und Florian van B\u00f6mmel. Dieser Fahrplan fasst die St\u00e4rken, Schw\u00e4chen, M\u00f6glichkeiten und Herausforderungen von HBV-Biomarkern zusammen.
\nhttps:\/\/www.nature.com\/articles\/s41575-022-00649-z<\/a>[\/et_pb_blurb][et_pb_blurb title=“Ethische Fragen bei der Rekrutierung \u00fcber soziale Medien f\u00fcr klinische Studien: Ethische Analyse und Rahmen“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/ethical-issues-in-social-media-recruitment-for-clinical-studies-ethical-analysis-and-framework.png“ alt=“Ethische Fragen bei der Rekrutierung \u00fcber soziale Medien f\u00fcr klinische Studien Ethische Analyse und Rahmen“ icon_placement=“left“ admin_label=“20220503″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]3 May and 7 September 2022 | The Journal of Medical Internet Research<\/span>
\nBettina M Zimmermann, Theresa Willem, Carl Justus Bredthauer, Alena Buyx<\/span>
\nSocial media recruitment for clinical studies holds the promise of being a cost-effective way of attracting traditionally marginalized populations and promoting patient engagement with researchers and a particular study. Die Nutzung sozialer Medien f\u00fcr die Rekrutierung von Teilnehmern an klinischen Studien wirft jedoch auch eine Reihe von ethischen Fragen auf. Die in diesem Beitrag zusammengefasste Studie soll einen umfassenden \u00dcberblick \u00fcber die ethischen Vorteile und Risiken geben, die bei der Rekrutierung \u00fcber soziale Medien in klinischen Studien zu ber\u00fccksichtigen sind, und praktische Empfehlungen f\u00fcr die Umsetzung dieser \u00dcberlegungen entwickeln.
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9115665\/<\/a>[\/et_pb_blurb][et_pb_blurb title=“Einem Heilmittel f\u00fcr Hepatitis B auf der Spur“ image=“https:\/\/www.thervacb.eu\/wp-content\/uploads\/closing-in-on-a-cure-for-hepatitis-b-1.png“ alt=“Einem Heilmittel f\u00fcr Hepatitis B auf der Spur“ icon_placement=“left“ admin_label=“20220330″ module_class=“blurbpublications“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“||50px||false|false“ link_option_url_new_window=“on“ header_font_size_tablet=““ header_font_size_phone=“18.01px“ header_font_size_last_edited=“on|phone“ global_colors_info=“{}“]<\/p>\n
ElieDolgin<\/span>
Mit der richtigen Kombination von Medikamenten k\u00f6nnte das Virus unter Kontrolle gebracht werden.
Lesen Sie weiter, um mehr dar\u00fcber zu erfahren, wie Ulrike Protzer und Mala Maini von TherVacB zusammen mit anderen f\u00fchrenden HBV-Wissenschaftlern, Virologen, Virusimmunologen und Hepatologen auf der ganzen Welt die Entwicklung eines auf die Heilung von HBV ausgerichteten Aktionsplans vorangetrieben haben, der auch die Perspektive der Patienten ber\u00fccksichtigt.
https:\/\/www.nature.com\/articles\/d41586-022-00812-1<\/a><\/p>\n
Anna D Kosinska, Julia Festag, Martin M\u00fcck-H\u00e4usl, Marvin M Festag, Theresa Asen, Ulrike Protzer<\/span>
W\u00e4hrend des nat\u00fcrlichen Verlaufs einer chronischen Infektion mit dem Hepatitis-B-Virus (HBV) geht das Hepatitis-B-e-Antigen (HBeAg) in der Regel verloren, w\u00e4hrend die direkte \u00dcbertragung von HBeAg-negativem HBV zu einer fulminanten Hepatitis B f\u00fchren kann. Die Induktion einer HBV-spezifischen Immunantwort durch eine therapeutische Impfung ist zwar eine vielversprechende, neuartige Behandlungsm\u00f6glichkeit f\u00fcr chronische Hepatitis B, aber es ist nach wie vor unklar, ob der Verlust von HBeAg die Wirksamkeit oder Vertr\u00e4glichkeit der Impfung beeinflussen kann. Wir haben daher einen AAV-Vektor entwickelt, der ein 1,3-fach \u00fcberlanges HBV-Genom mit einer typischen Stop-Codon-Mutation in der Pr\u00e4-Core-Region tr\u00e4gt und die Replikation von HBeAg(-)-HBV in M\u00e4uselebern initiiert. Die Infektion von C57BL\/6-M\u00e4usen f\u00fchrte zu einer persistenten HBeAg(-)-HBV-Replikation ohne nachweisbare Anti-HBV-Immunit\u00e4t oder Lebersch\u00e4den. HBV-Tr\u00e4germ\u00e4use wurden mit TherVacB immunisiert, einem therapeutischen Hepatitis-B-Impfstoff, der ein partikul\u00e4res HBV S und ein Kernprotein f\u00fcr die Grundimmunisierung und ein modifiziertes Vaccinia Ankara (MVA) f\u00fcr die Verst\u00e4rkungsimpfung verwendet. Die TherVacB-Immunisierung von HBeAg(+) und HBeAg(-) HBV-Tr\u00e4germ\u00e4usen f\u00fchrte zu einer wirksamen Induktion von HBV-spezifischen Antik\u00f6rpern und zum Verlust von HBsAg, aber nur zu leichten Lebersch\u00e4den. Intrahepatische, HBV-spezifische CD8-T-Zellen, die in HBeAg(-)-M\u00e4usen induziert wurden, exprimierten mehr IFN\u03b3, zeigten aber eine \u00e4hnliche zytolytische Aktivit\u00e4t. Dies deutet darauf hin, dass der Verlust von HBeAg die Leistung der therapeutischen Impfung durch die St\u00e4rkung der nicht-zytolytischen Effektor-Funktionen verbessert.
https:\/\/pubmed.ncbi.nlm.nih.gov\/34451966\/<\/a><\/p>\n
G\u00fcnter Froeschl, Michael Hoelscher, Lucas Henze Maganga, Inge Kroidl, Petra Clowes, Steffen Geis, Elmar Saathoff, Dieter Hoffmann, Ulrike Protzer, Arne Kroidl<\/span>
In Afrika s\u00fcdlich der Sahara gibt es eine hohe Pr\u00e4valenz f\u00fcr Hepatitis-B-Virus (HBV). Ziel dieser Analyse ist es, die HBV-Belastung verschiedener Altersgruppen in der Region Mbeya in Tansania zu kl\u00e4ren und die Pr\u00e4valenz von Hepatitis-C- (HCV) und Hepatitis-Delta-Antigen- (HDV) Infektionen zu bestimmen.
https:\/\/www.panafrican-med-journal.com\/content\/article\/39\/174\/full\/<\/a><\/p>\n
Ulrike Protzer<\/span>
K\u00fcrzlich wurden Tests auf Hepatitis B und C in die Gesundheitsvorsorge („Check-up“) aufgenommen. Versicherte ab 35 Jahren k\u00f6nnen sich einmalig auf diese beiden Erkrankungen untersuchen lassen. Dr. med. Ulrich Scharmer sprach dar\u00fcber mit der Virologin Prof. Dr. med. Ulrike Protzer, M\u00fcnchen.
https:\/\/www.hausarzt.digital\/medizin\/praevention\/screening-auf-hepatitis-b-und-c-gehoert-jetzt-zur-gesundheitsvorsorge-95051.html<\/a><\/p>\n
Till Bunse, Anna D. Kosinska, Thomas Michler und Ulrike Protzer <\/span>
Bei einer chronischen Infektion mit dem Hepatitis-B-Virus (HBV) sind die virusspezifischen T-Zellen rar und teilweise dysfunktional. Die therapeutische Impfung ist eine vielversprechende Strategie, um neue virusspezifische T-Zellen zu induzieren und zu aktivieren. Bei langj\u00e4hrigen oder hochgradigen HBV-Tr\u00e4gern reicht die therapeutische Impfung allein jedoch m\u00f6glicherweise nicht aus, um HBV zu heilen. Ein Grund daf\u00fcr ist die Beeintr\u00e4chtigung der antiviralen T-Zellen durch Immun-Checkpoints. In dieser Studie haben wir small-interfering RNA (siRNA) in Kombination mit einem heterologen therapeutischen Impfschema (TherVacB) verwendet, um einen wichtigen Immun-Checkpoint, die Interaktion von programmiertem Todesprotein-1 (PD-1) und seinem Liganden (PDL-1), zu st\u00f6ren. Bei M\u00e4usen, die nach einer Infektion mit einem Adeno-assoziierten Virus, das das HBV-Genom enth\u00e4lt, persistent HBV replizieren, f\u00fchrte siRNA, die auf PD-L1 abzielt, zu einer h\u00f6heren Funktionalit\u00e4t HBV-spezifischer CD8+ T-Zellen nach einer therapeutischen Impfung und erm\u00f6glichte eine nachhaltigere antivirale Wirkung und Kontrolle von HBV im peripheren Blut und in der Leber. Die antivirale Wirkung war ausgepr\u00e4gter, wenn PD-L1 w\u00e4hrend der Grundimmunisierung herunterreguliert wurde als w\u00e4hrend der Boost-Impfung. Thus, targeting PD-L1 using siRNA is a promising approach to enhance the efficacy of therapeutic vaccination and finally cure HBV.
https:\/\/www.mdpi.com\/2218-273X\/12\/3\/470<\/a><\/p>\n